Palisade Bio (PALI) Treasury Shares (2012 - 2025)

Palisade Bio (PALI) posted quarterly Treasury Shares of $24.8 million for Q4 2025, up 102593.12% quarter-over-quarter from $24195.0 in Q4 2023.

Palisade Bio (PALI) Treasury Shares (2012 - 2025) Analysis & Trends

Palisade Bio (PALI) has reported Treasury Shares for 11 consecutive years, with $24.8 million the latest figure, recorded in Q4 2025.

In Q4 2025, Treasury Shares changed N/A year-over-year to $24.8 million; the TTM figure through Dec 2025 stood at $24.8 million (changed N/A YoY), while the FY2025 annual figure was $24.8 million, changed N/A from the prior year.
Treasury Shares improved to $24.8 million in Q4 2025 per PALI's latest filing, from $24195.0 in the prior quarter.
Across five years, Treasury Shares topped out at $24.8 million in Q4 2025 and bottomed at $24195.0 in Q4 2023.
Historically, Treasury Shares has averaged $7.6 million across 4 years, with a median of $6.0 million in 2021.
Annual changes were most pronounced in 2021 — Treasury Shares jumped 612072.57% — and 2023, when it tumbled 97.06%.
Palisade Bio's Treasury Shares stood at $11.7 million in 2021, then changed by 0.0% to $11.7 million in 2022, then plunged by 99.79% to $24195.0 in 2023, then surged by 102593.12% to $24.8 million in 2025.
Business Quant data shows PALI's Treasury Shares at $24.8 million in Q4 2025, $24195.0 in Q4 2023, and $342970.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	5.08 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	2.72 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	92,219.00
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-

Download Data